Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2004 Sep 12;4:62. doi: 10.1186/1471-2407-4-62

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2004 Fensterle et al; licensee BioMed Central Ltd.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fraction of sera positive at different antibody levels. In A, the percentage of B-Raf positive sera of control patients (△) or melanoma patients (■) is plotted as a function of the cut off titer, whereas sera are termed positive if the titer reaches or exacerbates the given cut off titer. The difference between control patients and melanoma patients was statistically significant for a cut off titer of 1:300 (P = 0.028; 0.073; 1.0, two sided Fisher's exact test for cut off titers equal to 1:300; 1:900 and 1:2700 respectively). In B, the percentage of sera with titers higher or equal than 1:300 is shown for B-Raf V599E, B-Raf and C-Raf specific responses. In all cases, the amount of antibody positive melanoma patients is higher compared to the control group. This trend was significant for the comparison of B-Raf positive sera (P = 0.028, Fisher's exact test) and not significant for the comparison of B-Raf V599E (P = 0.12, Fisher's exact test). However, C-Raf specific antibodies with titers of 1:300 were only detectable in 1.8% of the tested sera from melanoma patients and none of the control patients (P = 0.327).